Charles River Laboratories International (NYSE:CRL) Price Target Cut to $228.00

Charles River Laboratories International (NYSE:CRLGet Free Report) had its price target cut by stock analysts at TD Cowen from $260.00 to $228.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the medical research company’s stock. TD Cowen’s price objective suggests a potential upside of 0.22% from the company’s previous close.

A number of other analysts have also commented on CRL. Evercore ISI boosted their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. boosted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. UBS Group boosted their target price on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, February 15th. TheStreet raised Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Finally, Robert W. Baird decreased their price objective on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating for the company in a report on Friday. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.27.

Check Out Our Latest Stock Report on CRL

Charles River Laboratories International Trading Down 0.3 %

Shares of CRL stock traded down $0.63 during mid-day trading on Monday, hitting $227.49. The company’s stock had a trading volume of 166,511 shares, compared to its average volume of 547,923. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The company’s fifty day simple moving average is $249.97 and its 200-day simple moving average is $226.26. The company has a market cap of $11.72 billion, a PE ratio of 26.71, a P/E/G ratio of 1.79 and a beta of 1.44. Charles River Laboratories International has a 52 week low of $161.65 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRLGet Free Report) last issued its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. As a group, equities research analysts expect that Charles River Laboratories International will post 11.01 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the transaction, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the transaction, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of CRL. Advisor Partners II LLC lifted its stake in Charles River Laboratories International by 2.7% in the third quarter. Advisor Partners II LLC now owns 2,393 shares of the medical research company’s stock valued at $469,000 after purchasing an additional 63 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter worth $795,000. ING Groep NV purchased a new stake in shares of Charles River Laboratories International during the third quarter worth $1,262,000. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Charles River Laboratories International by 1.9% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,245 shares of the medical research company’s stock worth $832,000 after acquiring an additional 79 shares in the last quarter. Finally, Mitchell & Pahl Private Wealth LLC lifted its position in shares of Charles River Laboratories International by 18.6% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 2,949 shares of the medical research company’s stock worth $578,000 after acquiring an additional 462 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.